Role of renin-angiotensin-aldosterone system in metabolic syndrome and obesity-related hypertension

Current Hypertension Reviews

Volumn 9, Issue 4, 2013, Pages 238-245

  Kamide, Kei ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ACEI; Aldosterone receptor blockers; ARB; Atherosclerosis; Insulin resistance; JNC 8; JSH 2014; Oxidative stress; Renin inhibitors; Renin angiotensin system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; INSULIN; RAMIPRIL; RENIN; RENIN INHIBITOR; TELMISARTAN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE; CELL CULTURE; CELL GROWTH; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IN VIVO STUDY; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR BIOLOGY; MORTALITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 84906912915     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/1573402110666140812122349     Document Type: Review

References (67)

1. Kamide K. Insulin resistance and the renin-angiotensin-aldosterone system in metabolic syndrome and obesity related hypertension. Curr Hypertens Rev. 2010; 6: 100-106.
2. Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253-392.
3. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507-20.
4. Mancia G, Farard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for themanagement of arterial hypertension. TheTask Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). J Hyperten 2013, 31: 1281-1357.
5. Page MR. Evidence based Diabetes Management. The JNC 8 Hypertension Guidelines: An In-Depth Guide Published Online: January 21, 2014 AJMC. COM: http://www.ajmc.com/publications/ evidence-based-diabetes-management/2014/jan-feb2014/the-jnc-8-hypertension-guidelines-an-in-depth-guide#sthash.K1SryzDD.dpuf.
6. Task Force Members: Mancia G, Guy De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) European Heart Journal 2007; 28: 1462-1536.
7. Zreikat HH, Harpe SE, Slattum PW, Mays DP, Essah PA, Cheang KI. Effect of Renin-Angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome. Metabolism 2014; 63: 3 92-9.
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145-153.
9. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359(9311): 995-1003.
10. Ferrari R, Boersma F. The impact of ACE inhibitor on all-cause and cardiovascular mortality in contemporary hypertension trials. Expert Review of Cardiovascular Therapy. J Am Coll Cardiol 2013; 11: 705-717.
11. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031.
12. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51(2): 393-398.
13. Gilbert CJ, Gomes T, Mamdani MM, et al. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers. Can J Cardiol 2013; 29: 586-591.
14. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12(Pt 3): 205S-213S.
15. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003; 4(2): 51-61.
16. Chae YK, Khemasuwan D, Dimou A, et al. Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic disease. PLoS One 2014; 9: e87813.
17. Kamide K, Rakugi H, Nagai M, et al. Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 1998; 32(3): 482-487.
18. Kamide K, Hori MT, Zhu JH, et al. Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000; 18(8): 1051-1056.
19. Tuck ML, Bounoua F, Eslami P, et al. Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens 2004; 22(9): 1779-85.
20. Nickenig G, Roling J, Strehlow K, Schnabel P, et al. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998; 98(22): 2453-2460.
21. Kamide K, Rakugi H, Nagai M, et al. Insulin-mediated modulation of the endothelial renin-angiotensin system and vascular cell growth. J Hypertens 2004; 22(1): 121-7.
22. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8(7): 731-737.
23. Sharma AM, Janke J, Gorzelniak K, et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40(5): 609-11.
24. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the reninangiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22(10): 1977-82.
25. Folli F, Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100(9): 2158-2169.
26. Gardner CD, Eguchi S, Reynolds CM, et al. Hydrogen peroxide inhibits insulin signaling in vascular smooth muscle cells. Exp Biol Med 2003; 228(7): 836-842.
27. Takeda M, Yamamoto K, Takemura Y, et al. Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes 2013; 62(1): 223-233.
28. Kamide K et al. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 1996; 9(12 Pt 1):1165-1171.
29. Kamide K, Rakugi H, Higaki J, et al. The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens 2002; 15(1 Pt 1): 66-71.
30. Hirose T, Hashimoto M, Totsune K, et al. Association of (pro)renin receptor gene polymorphisms with lacunar infarction and left ventricular hypertrophy in Japanese women: the Ohasama study. Hypertens Res 2011; 34: 530-535.
31. Kawai T, Ohishi M, Takeya Y, et al. Carotid plaque score and intima media thickness as predictors of stroke and mortality in hypertensive patients. Hypertens Res 2013; 36: 902-909.
32. Ohta Y, Kawano Y, Iwashima Y, et al. Control of home blood pressure with an amlodipine-or losartan-based regimen and progression of carotid artery intima-media thickness in hypertensive patients: the HOSP substudy. Clin Exp Hypertens 2013; 35(4): 279-84.
33. Kamide K, Rakugi H, Nakano N, et al. Insulin resistance is related to silent cerebral infarction in patients with essential hypertension. Am J Hypertens 1997; 10: 1245-9.
34. Kamide K, Rakugi H, Nakano N, et al. Insulin resistance is related to silent cerebral infarction in patients with essential hypertension. Am J Hypertens 1997; 10(11): 1245-1249.
35. Matayoshi T, Kamide K, Takiuchi S, et al. Relationship between insulin resistance and the renin-angiotensin system: analysis for patients with essential and renovascular hypertension. Clin Exp Hypertens 2007; 29(7): 479-87.
36. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006; 48(2): 239-45.
37. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27 (1): S79-S83.
38. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HAW, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761-1769.
39. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000; 321: 412-419.
40. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998; 317: 703-713.
41. Tanaka Y, Daida H, Imai Y, et al. Morning gome blood pressure may be a signifuicant marker of nephropathy in Japanese patients with type 2 diabetes: ADVANCED-J study 1. Hypertens Res 2009; 32: 770-774.
42. Hamet P. What matters in ADVANCE and ADVANCE-ON. Diabetes Obes Metab 2012; 14 (1): 20-29.
43. Hovens MM, Tamsma JT, Beishuizen ED, Huisman MV. Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update. Drugs 2005; 65(4): 433-45.
44. Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep 2011; 13(6): 452-5.
45. Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol 2012; 10: 156-161.
46. Tandon N, Ali MK, Narayan KM. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Am J Cardiovasc Drugs 2012; 12(1): 7-22.
47. Yki-Jarvinen H. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs 2000; 60(5): 975-983.
48. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitorsand calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
49. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
50. Strauss MH, Hall AS. Do angiotensin receptor blockers increase the risk of myocardial infarction?: Angiotensin Receptor Blockers May increase risk of Myocardial Infarction: Unraveling the ARBMI Paradox. Circulation 2006; 114: 838-854.
51. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensinconverting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensinaldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33: 2088-2097.
52. Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res 2013; 50(2): 89-99.
53. Ramachandran S, Vasan MD, Jane C, Evans DS., Martin G. Larson, Sc.D., Peter W.F. Wilson, M.D., James B. Meigs, M.D., M.P.H., Nader Rifai, Emelia J. Benjamin, M.D., and Daniel Levy, M.D. Serum aldosterone and incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41.
54. Hilege HL, Girbes AR, de Kam PJ, et al. Renal Function, Neurohormonal Activation, and Survival in Patients With Chronic Heart Failure. Circulation 2000; 102: 203-210.
55. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.
56. Weinberger MH, Roniker B, Krause S, Weiss RJ. Eplerenon, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 16: 709-716.
57. Burgess ED, Lacourclere Y, Ruilope-Urioste LM, et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Therapeutics 2003; 25: 2388-2404.
58. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy. Hypeertension 2003; 41: 64-68.
59. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin-Angiotensin-Aldosterone System 2007; 8: 190.
60. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
61. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensinconverting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276-284.
62. Littlejohn TW 3rd, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009; 25: 951-959.
63. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
64. Seed A, Gardner R, McMurray J, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007; 9: 1120-1127.
65. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients. Circulation 2005; 111: 1012-1018.
66. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398-2404.
67. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffer SM, Solomon SD. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213.